COVID-19. COVID-19
Conditions
Interventions
Intervention 1: Intervention group:400mg of Sofosbovir and Vitamin B1300 control group. Intervention 2: Control group: Vitamin B1300.
Sponsors
Ahvaz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Outpatients presented with positive PCR and mild clinical signs without pulmonary involvement on CT scan As defined by patient with sore throat dry cough loss of sense of smell and taste nausea and vomiting O2 Sat = 95 T <38 RR <24 stable pulse and blood pressure body aches
Exclusion criteria
Exclusion criteria: y>18 Organ transplant Severe skin history including TEN or Steven JohnsonAllergy to the studied drug The patient has previously been treated with this drug for other reasons Hepatitis C Not able to take pills Lack of awareness Be treated with anticonvulsant drugs Have fever and respiratory symptoms from 2 weeks ago Be treated with immunosuppressive drugs Be pregnant or breastfeeding 1 month ago received antiviral drugs for Covid-19 ESRD Advance CKD Advance liver disease Pulmonary Advance Disease Cardiac Advance Disease Advance Disease Hematology Solid tumor Cancer of neurological diseases such as CVA your situationG6PD deficient Be pregnant or breastfeeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Shortness of breath. Timepoint: day 14 or sooner at the discretion of the physician. Method of measurement: Clinical evaluation. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMaryam Hadad Zade Shoushtary
Ahvaz University of Medical Sciences
Outcome results
None listed